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ABSTRACT The unbalanced excitatory/inhibitory
neurotransmitter function in the neuronal network
afflicted by seizures is the main biochemical and bio-
physical hallmark of epilepsy. The aim of this work was
to identify changes in the signaling mechanisms associ-
ated with neuropeptide Y (NPY)-mediated inhibition of
glutamate release that may contribute to hyperexcitabil-
ity. Using isolated rat hippocampal nerve terminals, we
showed that the KCl-evoked glutamate release is inhib-
ited by NPY Y2 receptor activation and is potentiated by
the stimulation of protein kinase C (PKC). Moreover,
we observed that immediately after status epilepticus (6
h postinjection with kainate, 10 mg/kg), the functional
inhibition of glutamate release by NPY Y2 receptors was
transiently blocked concomitantly with PKC hyperacti-
vation. The pharmacological blockade of seizure-acti-
vated PKC revealed again the Y2 receptor-mediated
inhibition of glutamate release. The functional activity
of PKC immediately after status epilepticus was as-
sessed by evaluating phosphorylation of the AMPA
receptor subunit GluR1 (Ser-831), a substrate for PKC.
Moreover, NPY-stimulated [35S]GTPS autoradio-
graphic binding studies indicated that the common
target for Y2 receptor and PKC on the inhibition/
potentiation of glutamate release was located down-
stream of the Y2 receptor, or its interacting G-protein,
and involves voltage-gated calcium channels.—Silva,
A. P., Lourenc¸o, J., Xapelli, S., Ferreira, R., Kristiansen,
H., Woldbye, D. P. D., Oliveira, C. R., Malva, J. O.
Protein kinase C activity blocks neuropeptide Y-medi-
ated inhibition of glutamate release and contributes to
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Neuropeptide y (npy) has been implicated in several
centrally mediated physiological functions such as reg-
ulation of circadian rhythms, body temperature, sexual
behavior, blood pressure, appetite, and neuroendo-
crine secretions (1–3). This peptide has also been
shown to modulate anxiety-related disorders and cog-
nitive functions such as learning and memory (4), and
it has been widely suggested to be involved in epilepto-
genesis and epilepsy (5–7). Moreover, the broad phys-
iological actions of NPY are transduced by at least five
cloned NPY receptors subtypes (Y1, Y2, Y4, Y5, and y6),
which belong to the G-protein-coupled receptor super-
family (8). NPY and NPY Y1, Y2, and Y5 receptors are
particularly abundant in the hippocampus, where they
play a major role in regulating glutamate release (3, 9).
Endogenous NPY seems to play a major role in
regulating seizure activity, and this is supported by the
massive increase of NPY levels under epileptic condi-
tions in both inhibitory interneurons and excitatory
granule cells (5, 10). Moreover, seizure-related increase
in NPY expression is accompanied by modified levels of
NPY receptor subtypes in the hippocampus (11), and it
seems that more than one receptor subtype could be
responsible for mediating the antiepileptic effects of
NPY, but clearly Y2 and/or Y5 receptors are key players
(10, 12, 13). It was reported that NPY-deficient mice
have increased susceptibility to seizures induced by
pentylenetetrazol or kainate and that seizure activity
was reduced in rat models of NPY overexpression
(14–17). Furthermore, NPY acting via Y2 receptors can
inhibit excitatory synaptic transmission (18, 19), the
release of glutamate (20, 21), and epileptiform activity
(10, 22) in hippocampal slices. NPY was also found to
inhibit kainate-induced seizures via Y5 receptors (13,
23), but recently El Bahh and collaborators (12) dem-
onstrated that Y2 receptors play a key role in the
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antiepileptic properties of NPY in the hippocampus.
Recently, we observed that in different stages of the
epileptogenic process, the ability of different NPY re-
ceptors to modulate the release of glutamate is
changed (21). We suggested that in the acute phase of
epilepsy, a transient loss of NPY-mediated inhibition of
glutamate release might be associated with hyperexcit-
ability of the hippocampal neuronal network and sei-
zure activity. After the acute phase, an adaptation of the
NPYergic modulation of glutamate release was identi-
fied and the inhibitory effect of NPY was again close to
control levels (21).
It is well established that protein kinase A- and
C-mediated substrate phosphorylation is implicated in
a broad spectrum of neuronal events, including neuro-
nal differentiation, process outgrowth, axonal regener-
ation (24–26), glutamate-induced neurotoxicity (27),
and neurotransmitter release (28, 29). It has also been
shown that protein kinases act on exocytotic machinery
(30) and modulate ion channels (29, 31) and receptor
activity/function (32).
Taken together, the current data indicate that NPY
receptors clearly play a role in normal physiological
conditions, as well as in response to pathological hyper-
activity in the hippocampus (6, 21, 33, 34). Yet despite
the role of these receptors already mentioned, there is
little consensus about the intracellular signaling path-
way (or pathways) that can interfere with their function
under pathological conditions such as epilepsy.
MATERIALS AND METHODS
Rodent model of temporal lobe epilepsy
Male Wistar rats 6–7 wk of age were used. Kainate (KA; Ocean
Produce International, Shelburne, Nova Scotia, Canada) was
dissolved in a maximum volume of 500 l of sterile 0.9% NaCl
and injected intraperitoneally (i.p.) at a dosage of 10 mg/kg
body wt. The control group of animals was injected with the
same volume of saline (21). Rats were observed for at least 3 h
and their behavior was rated as described previously (35). All
the animals used in the present work achieved status epilep-
ticus and were sacrificed 6 h or 24 h after KA injection.
All procedures involving experimental animals were per-
formed in accordance with European Community guidelines.
All efforts were made to minimize animal suffering and to
reduce the number of animals used.
Preparation of rat hippocampal synaptosomes
A partially purified synaptosomal fraction (P2) was isolated
from hippocampi or from hippocampal subregions CA1,
CA3, and dentate gyrus (DG) of male Wistar control or
epileptic rats (sacrificed 6 h or 24 h after KA injection),
essentially as described for brain cortex (36), with some
modifications (21, 37, 38). The hippocampi were homoge-
nized in 0.32 M sucrose, 10 mM HEPES-Na, pH 7.4, using a
Thomas B-Potter homogenizer (Thomas Scientific, Swedes-
boro, NJ, USA) and centrifuged at 3000 g for 2 min. The
pellet obtained was resuspended, followed by sedimentation
at the same speed. The combined supernatants were spun for
12 min at 14,600 g and a P2 pellet was obtained. The upper
white layer of the pellet containing synaptosomes (39) was
removed with a small spoon and resuspended in the same
sucrose medium used before.
Coronal slices of hippocampus (800 m-thick) were pre-
pared for isolation of the synaptosomes from hippocampal
subregions (CA1, CA3, and DG) of nonepileptic and epileptic
rats (6 h and 24 h after KA injection). In each slice, the
fimbria and the subiculum were separated from the rest of
the slice under stereomicroscopic observation. CA3 subslices
were obtained by separation from CA1 and DG, and the last
separation (CA1 from DG) was performed through the
hippocampal sulcus (38). The pooled subslices were homog-
enized in the sucrose medium using a Thomas AA-Potter,
transferred to Eppendorf tubes, and centrifuged as described
for the isolation of whole hippocampal synaptosomes. The
protein concentration was determined by the Biuret method
(40) for glutamate release experiments, and the synapto-
somes were stored as drained pellets containing 1 mg of
protein.
Preparation of hippocampal lysates
For Western blot analysis, the hippocampi or hippocampal
subregions (CA1, CA3, and DG) of male Wistar control or
epileptic rats (sacrificed 6 h or 24 h after KA injection) were
removed as described in the foregoing section. Then the
tissue was individually homogenized with 40 strokes in a glass
homogenizer in 50 mM Tris-HCl, 0.5% Triton X-100, supple-
mented with 100 M phenylmethanesulfonyl fluoride, 1 mM
dithiothreitol (DTT), 1 g/ml chymostatin, 1 g/ml leupep-
tin, 1 g/ml antipain, 5 g/ml pepstatin A (all from Sigma
Chemical Co., St. Louis, MO, USA), pH 7.4, at 4°C. Protein
concentration was determined by the bicinchoninic acid
method (41).
Measurement of glutamate release
The release of endogenous glutamate was followed using a
continuous fluorimetric assay as described previously (42),
with some modifications (37, 38). Synaptosomes (1 mg pro-
tein) were preincubated for 20 min at 37°C in the following
medium (in mM): 132 NaCl, 1 KCl, 1 MgCl2, 1.2 H3PO4, 0.1
CaCl2, 10 glucose, 10 HEPES-Na, pH 7.4, with 0.1% fatty
acid-free BSA. After this period, NPY or Y1, Y2, or Y5 receptor
agonists ([Leu31, Pro34]NPY, NPY(13–36) or NPY(19–23)-
(Gly1, Ser3, Gln4, Thr6, AL31, Aib32, Gln34)-PP, respectively)
(Bachem AG, Bubendorf, Switzerland), antagonists
[BIBP3226 (Peninsula Labs, Belmont, CA, USA), BIIE0246
(kindly provided by Dr. Henri Doods, Boehringer Ingelheim
Pharma KG, Germany) and L-152,804 (Tocris, Bristol, UK),
respectively], and/or PKA and PKC activator/inhibitor [8-Br-
cAMP/H-89 and phorbol myristate acetate (PMA)/bisindoyl-
maleimide I (BIS), respectively] (all from Sigma Chemical
Co.), were added to the incubation medium for an additional
10 min. Synaptosomes were then centrifuged at 15,800 g and
resuspended in 1 ml of the same medium without BSA
containing 1 mM CaCl2. The suspension was transferred to a
stirred acrylic cuvette, maintained at 37°C, followed by the
addition of 1 mM NADP, 50 U of purified glutamate
dehydrogenase, and again NPY receptor agonists or antago-
nists. Fluorescence was measured using a Perkin-Elmer model
LS-5B luminescence spectrometer (Perkin-Elmer Ltd, Bea-
consfield, Buckinghamshire, England) at the excitation and
emission wavelengths of 340 nm and 460 nm, respectively,
with excitation and emission slits of 5 nm and 10 nm,
respectively. The data were collected at 0.5 s intervals and at
the end of each experiment, 2.5 nmol of l-glutamate was
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added as a calibration to allow quantification of released
glutamate.
Glutamate release was monitored for 11 min and synapto-
somes were stimulated 4 min after the beginning of each
experiment with 15 mM KCl or 5 M ionomycin.
Western blot analysis
Twenty-five micrograms of protein from total hippocampus
or from hippocampal subregions were separated by SDS-
PAGE on 7.5% acrylamide/bisacrilamide gels, using a
Bicine/SDS-based electrophoresis buffer (pH 8.3), and trans-
ferred onto PVDF membranes (750 mA, 50 min at 4°C in a
solution containing 10 mM CAPS and 10% methanol, pH
11.0) (43). Membrane blocking was performed for 1 h at
room temperature in Tris-buffered saline containing 5%
low-fat milk and 0.1% Tween 20. Primary antibodies raised
against GluR1 and phospho-GluR1 (Ser-831) (both from
Upstate, Barcelona, Spain) were applied overnight at 4°C and
were detected using alkaline phosphatase conjugated second-
ary antibodies. Immunoblots were visualized using the En-
hanced ChemiFluorescence detection reagent and a Versa
Doc 3000 imaging system (Bio-Rad, Hercules, CA, USA).
Immunohistochemistry
Rats were deeply anesthetized with sodium pentobarbital
(120 mg/kg, i.p.) and perfused transcardially first with PBS,
then fixed with 4% paraformaldehyde in PBS. Brains were
removed and coronal sections (20 m) were cut on a cryostat.
Brain sections placed on gelatin-coated glass slides were
washed with 0.05 M Tris-buffered saline (TBS) for 15 min.
Afterward the sections were sequentially incubated with 1%
Triton three times for 15 min each, 10% FBS for 30 min and
with antiphospho-GluR1 (Ser-831) for 2 days at 4°C (1:200;
Upstate, Barcelona, Spain). After 30 min at room tempera-
ture, sections were washed again three times in 1% Triton for
15 min each, incubated for 1 h with anti-rabbit Alexa 488
(1:200; Molecular Probes, Leiden, The Netherlands), and
stained with Hoescht 33342 (Molecular Probes) for 5 min.
Finally, sections were washed (TBS), mounted with DakoCy-
tomation fluorescent mounting medium (Dako, Glostrup,
Denmark), coverslipped, and examined in a Fluorescence
Microscope (Zeiss Axioskop 2 Plus).
NPY stimulated [35S]GTPS binding autoradiography
The brains obtained from control and epileptic rats were cut
in coronal sections (20 m) at –20°C, thaw mounted onto
Superfrost slides, and dried on a hot plate. Tissue sections
were stored at –80°C until further processing.
A slightly modified method of Sim and collaborators (44)
was used. Briefly, sections were air dried for 30 min at room
temperature (RT) before being rehydrated in assay buffer A
(50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM NaCl;
pH 7.4) for 10 min (RT). Subsequently, a 20 min (RT)
preincubation was performed in assay buffer B (assay buffer
A0.2 mM DTT, 2 mM GDP, 1 M DPCPX (1,3-dipropyl-8-
cyclopentylxanthine), 0.5% BSA (and NPY receptor antago-
nist, if applicable), followed by incubation in assay buffer B 
40 pM [35S]GTPS (1250 Ci/mmol, Perkin-Elmer, Den-
mark), 3 M NPY, and/or NPY receptor antagonists or PKC
activator/inhibitor (Sigma Chemical Co.) for 2 h at 25°C. In
each experiment, basal binding was determined by omitting
the application of NPY receptor ligands and nonspecific
binding by applying 10 M unlabeled GTPS (Perkin-Elmer,
Norwalk, CT, USA). The incubation was terminated by 2  5
min washing in ice-cold 50 mM Tris-HCl buffer (pH 7.4),
followed by a brief rinse in cold deionized water. Sections
were subsequently dried and exposed to Kodak BioMax MR
film for 4 days together with 14C standards (Amersham Life
Sciences, Piscataway, NJ, USA). The films were developed in
Kodak D19 developer. Optical densities were measured bilat-
erally over the dorsal CA1 (pyramidal layer, strata oriens, and
radiatum) and CA3 (pyramidal layers, strata oriens, radiatum,
and lucidum) as well as DG (molecular layer) using computer-
assisted image analysis (Scion Image® analysis program).
Right and left side values were averaged per section and used
to calculate the mean of each animal. Background measure-
ments immediately adjacent to each brain section were sub-
tracted from each measurement before calculations. The
percent of stimulation above basal level was calculated as
[(Stim.–Basal)/Basal]*100%.
The following compounds were used for these experi-
ments: NPY (3 M, Bachem AG, Bubendorf, Switzerland),
BIBP3226 (30 M; Bachem AG), BIIE0246 (30 M; Tocris
Cookson Ltd., UK), L-152,804 (30 M; Tocris) PMA (300
nM), and BIS (3 M). The NPY Y2 receptor population was
determined using NPY in the presence of NPY Y1 (BIBP3226)
and NPY Y5 (L-152,804) receptor antagonists. Total blocking
of the NPY stimulation was obtained adding a mixture of
BIBP3226, BIIE246, and L-152,804.
Statistical analysis
The data are expressed as means  se. Statistics were per-
formed using an ANOVA (one-way ANOVA), followed by
Dunnett’s or Bonferroni’s post-tests, as indicated in the figure
legends.
RESULTS
Modulation of glutamate release by NPY receptors in
rat hippocampal synaptosomes: cross-talk with PKA or
PKC pathway
We have shown that the activation of Y1, Y2, or Y5
receptors with selective agonists inhibited KCl-evoked
glutamate release in hippocampal synaptosomal prep-
arations and that these inhibitory effects were pre-
vented by their selective NPY receptor antagonists (38,
45). Moreover, we also showed that the inhibition
induced by NPY (endogenous agonist, full sequence)
was due to the activation of Y2 receptors and not Y1 or
Y5 subtypes (45). With the present study, we intended
to clarify the possible involvement of PKA and/or PKC
in the inhibitory effect mediated by NPY receptors
under control and epileptic conditions.
In hippocampal synaptosomes prepared from con-
trol rats, the total KCl-evoked release of glutamate was
0.9  0.04 nmol glutamate/mg protein/min, and the
inhibitory effect mediated by NPY (Fig. 1A, B) or by Y1,
Y2, Y5 receptor agonists (Fig. 2A–C) was not significantly
modified by either activation of PKA with the cAMP
analog 8-bromo-cAMP (500 M 8-Br-cAMP) or by inhi-
bition with H89 (1 M). The inhibition of glutamate
release induced by NPY or by the activation of Y1, Y2, Y5
receptor plus 500 M 8-Br-cAMP was 61.5  6.6%,
63.0  3.6%, 64.7  3.5%, or 68.6  4.0% of control,
respectively, and the PKA activator by itself was without
effect (91.54.9% of control). Similar results were
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obtained in the presence of 1 M NPY (Fig. 1B), 1 M
[Leu31, Pro34]NPY (Fig. 2A), 300 nM NPY(13–36) (Fig.
2B), or 1 M NPY(19–23)-(Gly1, Ser3, Gln4, Thr6, AL31,
Aib32, Gln34)-PP (Fig. 2C) plus 1 M H89 as follows:
65.8  3.3%, 59.3  3.1%, 63.8  1.8%, 70.4  3.5% of
control, respectively. Again, the inhibitor of PKA (H89)
by itself had no effect (91.84.3% of control). All these
observations allow us to conclude that PKA was not
interfering with the inhibition of glutamate release
mediated by NPY receptor activation.
PKC-mediated substrate phosphorylation has been
implicated in a broad spectrum of neuronal events,
including neurotransmitter release (28). Indeed, acti-
vation of PKC by phorbol esters leads to an increase in
neurotransmitter release from nerve terminals of hip-
pocampal slices (46), from nerve terminals in the spinal
cord (47), and from isolated nerve terminals from
mammalian brain (48, 49). In agreement with these
studies, the activation of PKC with 300 nM PMA in-
duced an increase in KCl-evoked glutamate release to
129.7  3.0% of control (Figs. 1, 2), which was blocked
by the PKC inhibitor (BIS) to 99.3  6.6% of control
(Figs. 1B, 2). By itself, 1 M BIS did not induce any
significant effect (92.55.4% of control). Moreover,
the inhibitory effect induced by 1 M [Leu31,
Pro34]NPY (Fig. 2A) or 1 M NPY(19–23)-(Gly1, Ser3,
Gln4, Thr6, AL31, Aib32, Gln34)-PP (Fig. 2C) was not
affected by the simultaneous activation of PKC
(100.07.3% or 93.88.0% of control, respectively),
keeping in mind that PMA by itself increased glutamate
release to 129.7  3.0% of control. However, this was
not the case concerning NPY or Y2 receptor activation,
since in the simultaneous presence of NPY or Y2
receptor agonist plus PMA, glutamate release was
133.2  2.2% (Fig. 1B) or 133.8  2.9% (Fig. 2B) of
control, respectively. Moreover, the inhibitory effect
mediated by 1 M NPY (66.04.7% of control) or 300
nM NPY(13–36) (71.01.2% of control) was recovered
in the presence of the PKC inhibitor to 68.9  2.6% or
65.0  5.4% of control, respectively (Fig. 1B, Fig. 2B).
The PKC inhibitor by itself (1 M BIS) did not affect
the inhibition induced by Y1 (Fig. 2A), Y2 (Fig. 2B), Y5
(Fig. 2C) receptor agonists or NPY (Fig. 1B)
(75.82.9%, 67.05.5%, 63.63.4%, or 68.23.2% of
control, respectively). These results show that, under
control conditions, the pharmacological activation of
PKC blocks the inhibition of glutamate release medi-
ated by the activation of Y2 receptors.
Involvement of PKC in the modulation of glutamate
release by Y2 receptors in hippocampal synaptosomes
obtained from epileptic rats
Several studies have demonstrated significant alter-
ations in PKC expression and subcellular distribution
in the hippocampus after KA treatment (50, 51). To
investigate the role of PKC in the inhibition of gluta-
mate release induced by Y2 receptor activation under
epileptic conditions, we injected rats with 10 mg/kg KA
(i.p.), a well-established model of epileptogenesis, as
described in Materials and Methods. Using synapto-
somes obtained from rats sacrificed 6 h postinjection,
we observed that the total KCl-evoked release of gluta-
mate was 1.1  0.03 nmol glutamate/mg protein/min
and that none of the agonists alone or in the presence
of the PKC activator had an inhibitory effect (Fig. 3A).
The values obtained with 1 M NPY, 300 nM NPY(13–
36), 1 M NPY plus 300 nM PMA, or 300 nM NPY(13–
36) plus 300 nM PMA were 94.1  3.3%, 93.4  3.3%,
93.7  3.1%, or 96.0  4.5% of control, respectively
(Fig. 3A). Moreover, 1 M BIS did not modify the
KCl-evoked glutamate release (108.04.0% of control);
in contrast to what happened under control conditions,
300 nM PMA by itself had no effect (100.23.9% of
control) (Fig. 3A). However, after inhibition of PKC
Figure 1. Representative recording of the effect of NPY (1
M) or PMA (300 nM) (A) on the 15 mM KCl-evoked
glutamate release in hippocampal synaptosomes (1 mM Ca2
present in the external medium). Quantitative analysis of the
effect of NPY (1 M) (B) on glutamate release from hip-
pocampal synaptosomes depolarized with 15 mM KCl in the
absence or presence of PKA activator (500 M 8-bromo-
cAMP)/inhibitor (1 M H89) or PKC activator (300 nM
PMA)/inhibitor (1 M BIS). Results represent the mean  se
of 4 to 9 independent experiments in different synaptosomal
preparations. **P  0.01, Dunnett’s post-test, statistical sig-
nificance when compared with control (KCl stimulation).
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Figure 2. Involvement of PKA or PKC on the inhibition of
glutamate release mediated by NPY Y1, Y2, or Y5 receptor
activation in rat hippocampal synaptosomes. Quantitative
analysis of the effect of 1 M [Leu31, Pro34]NPY (A), 300 nM
NPY(13–36) (B), 1 M NPY(19 –23)-(Gly1, Ser3, Gln4,
Thr6, AL31, Aib32, Gln34)-PP (C) on glutamate release from
hippocampal synaptosomes depolarized with 15 mM KCl in
the absence or in the presence of PKA activator (500 M
8-bromo-cAMP)/inhibitor (1 M H89) or PKC activator (300
nM PMA)/inhibitor (1 M BIS). Results represent the
mean  se of 4 to 9 independent experiments in different
synaptosomal preparations. **P  0.01, Dunnett’s post-test,
statistical significance when compared with control (KCl
stimulation).
Figure 3. Involvement of PKC on the inhibition of glutamate
release mediated by NPY or Y2 receptor activation in epileptic
rats. Quantitative analysis of the effect of 1 M NPY or 300 nM
NPY(13–36) on glutamate release evoked by 15 mM KCl
depolarization in hippocampal synaptosomes obtained from
epileptic rats sacrificed 6 h (A) or 24 h (B) postinjection.
Status epilepticus was induced in rats after injection with KA
(10 mg/kg) as described in Material and Methods. Results
represent the mean  se of 3 to 7 independent experiments
in different synaptosomal preparations. **P  0.01, Dun-
nett’s post-test, statistical significance when compared with
control (KCl stimulation).
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with 1 M BIS, we again observed a significant inhibi-
tory effect caused by 1 M NPY (70.03.6% of control)
or by 300 nM NPY(13–36) (71.02.3% of control) (Fig.
3A). Taking in consideration that 6 h after kainate
administration cells can be in a depolarized state and
still have increased calcium levels, we performed addi-
tional experiments in which we observed that in synap-
tosomes obtained from epileptic rats sacrificed 6 h
postinjection, the P-/Q-type VGCC blocker -agatoxin
IVA (100 nM) inhibited glutamate release to 51% of
control (data not shown), similar to what we observed
earlier in control animals (45). These results show that
the functional release of glutamate is fully functional in
epileptic rats and is not blocked due to increased levels
of presynaptic calcium.
The results obtained 24 h post-injection were similar to
the control situation (Fig. 3B). The total KCl-evoked
release of glutamate was 1.1  0.1 nmol glutamate/mg
protein/min; 1 M NPY or 300 nM NPY(13–36) inhibited
KCl-evoked glutamate release to 62.0  1.4% or 68.6 
1.4% of control, respectively (Fig. 3B). Again, PMA by
itself potentiated the release of glutamate to 136.3 3.1%
of control, and in the presence of NPY or the Y2 receptor
agonist, glutamate release was 137.8  4.0% or 135.0 
3.7% of control, respectively. Moreover, as observed un-
der control conditions, 1 M BIS by itself was without
effect (98.27.6% of control) and completely blocked
the potentiation of glutamate release induced by PMA
(105.07.0% of control) (Fig. 3B). Based on these results,
we suggest that at 6 h postinjection PKC is highly active
and occludes the inhibition of glutamate release medi-
ated by Y2 receptors.
Figure 4. Western blot analysis of the changes in GluR1 (A, B)
or phospho-GluR1 (C, D) levels in hippocampal subregions
(CA1, CA3, DG) of control rats (injected with saline) and
epileptic rats sacrificed 6 h (A, C) or 24 h (B, D) after KA
injection (10 mg/kg, i.p.). Results are expressed as mean
percentage of control  se of 3 or 4 independent experi-
ments. ***P  0.001, **P  0.01. Bonferroni’s post-test,
statistical significance when compared with CA1, CA3, or DG
from control rats.
Figure 5. Representative fluorescence microscopy images of
phospho-GluR1 (Ser-831) immunoreactivity in the CA1 pyra-
midal cell layer of the hippocampus of control rats (A) or
epileptic rats injected with KA (10 mg/kg) and sacrificed 6 h
(B) or 24 h (C) postinjection. There is an increase of
immunoreactivity against phospho-GluR1 (Ser-831) in ani-
mals with seizures. At 6 h postinjection (B), punctuate-like
labeling is clearly visible, suggesting a synaptic localization
(arrows), whereas after 24 h (C) immunoreactivity is distrib-
uted along neurites (arrows). Brain slices (20 m) were
labeled with antiphospho-GluR1 (Ser-831) (green) and
stained with Hoescht 33342 (blue). Scale: 50 m.
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GluR1 and phospho-GluR1 (Ser-831) levels in
hippocampal subregions of control and epileptic rats
The results described above suggest that in the acute
phase of epilepsy, PKC may be strongly activated and
that this effect can be associated with the loss of Y2
receptor-mediated inhibition of glutamate release. To
assess whether PKC is active under these conditions, we
decided to investigate the levels of phospho-GluR1
(Ser-831) as an indication of PKC activity. AMPA recep-
tors containing the GluR1 subunit may be regulated by
extracellular signals acting through PKC (52, 53). In-
deed, PKC phosphorylates Ser-831 of the GluR1 sub-
unit (54) and can contribute to modulate synaptic
transmission. Thus, we evaluated the levels of GluR1
and phospho-GluR1 in hippocampal subregions of
control and epileptic rats.
In hippocampal subregions CA1, CA3, and DG,
GluR1 levels at 6 h or 24 h postinjection were not
significantly different from those of control (Fig. 4A,
B). In contrast, phospho-GluR1 (Ser-831) levels ro-
bustly increased at 6 h (253.725.3% of control), and
even more pronounced 24 h postinjection in the CA1
subregion (1325.6267.4% of control) (Fig. 4C, D). No
significant effects were seen in the DG at any time point
after KA injection (Fig. 4C, D).
In the CA1 subregion, we observed an increase of
immunoreactivity against phospho-GluR1 (Ser-831) in
animals with seizures (Fig. 5). At 6 h postinjection (Fig.
5B), punctuate-like labeling was clearly visible, suggesting
a synaptic localization, whereas after 24 h the immuno-
reactivity was distributed along neurites (Fig. 5C).
Characterization of the intracellular mechanisms by
which PKC activity blocks NPY-mediated inhibition of
glutamate release
To study both the distribution and functionality of the
NPY receptors under control and epileptic conditions,
we performed functional autoradiographic studies. Ta-
ble 1 and Fig. 6A–C show levels of [35S]GTPS binding
in CA1, CA3, and DG after stimulation with 3 M NPY.
This effect was completely blocked by a mixture of Y1,
Y2, and Y5 receptor antagonists (30 M BIBP322630
M BIIE024630 M L-152,804) (Fig. 6D). Activation
of the Y2 receptor subtype (3 M NPY30 M
BIBP322630 M L-152,804) only induced an in-
creased binding signal above basal binding in the CA1
and CA3 subregions, correlating with the binding pat-
tern observed for the Y2 receptor in traditional autora-
diographic studies (55) (Table 1; Fig. 6E). Moreover,
the PKC activator (PMA) and/or inhibitor (BIS) did
not significantly alter the total NPY receptor or Y2
receptor-mediated [35S]GTPS binding under either
control or epileptic conditions (6 h postinjection)
(Table 1; Fig. 6). These results suggest that the function
of the NPY receptors is similar under control vs.
epileptic conditions. Moreover, PKC does not seem to
directly modulate the activity of NPY receptors, suggest-
ing that the PKC target is located downstream the
receptor level.
We previously showed that none of the NPY receptor
agonists used currently could reduce ionomycin-
induced glutamate release (45). Accordingly, in Fig.
7 we observed that PMA by itself (100.03.9% of
control) or in the presence of NPY (86.52.3% of
control) or NPY(13–36) (93.82.5% of control) did
not significantly potentiate or inhibit glutamate re-
lease, in contrast to what happened when we stimu-
lated glutamate release with KCl (Fig. 1B, Fig. 2B); 1
M BIS or 1 M BIS  1 M NPY had no effect (data
not shown). Since ionomycin promotes calcium in-
flux and glutamate release independently of voltage-
gated Ca2 channels (VGCCs) activity, the present
results suggest that PKC is acting on VGCCs, increas-
ing Ca2 conductance and thereby occluding the
inhibitory effect of Y2 receptors.
TABLE 1. Effect of PKC activator (PMA) or inhibitor (BIS) on NPY-stimulated 35S	GTPS binding in adult control and epileptic rat
hippocampal subregionsa
Percentage increase above basal 35S	GTPS binding (meanse, n 
 6–8)
NPY Y2
b
Region PMA BIS PMABIS PMA PMABIS
CA1
Control 63  6 51  6 66  7 66  11 33  3 31  9 45  5
Epileptic 82  9 58  13 74  14 78  18 41  5 38  18 59  10
CA3
Control 70  12 57  9 75  11 74  12 56  10 54  13 58  13
Epileptic 74  11 59  9 72  12 74  15 63  12 48  10 73  13
DG
Control 41  5 33  5 45  7 48  9 0 0 2  5
Epileptic 57  8 45  8 52  9 57  9 10  9 1  13 18  7
aControl rats were injected with saline (0.9% NaCl); epileptic seizures were induced with KA (10 mg/kg, i.p. injection) and rats were
sacrificed 6 h postinjection. Brain sections were processed as described in Materials and Methods. CA1, regio-superior cornu ammonis; CA3,
regio-inferior cornu ammonis; DG, dentate gyrus. bThe NPY Y2 receptor population was determined using NPY in the presence of NPY Y1
(BIBP3226) and NPY Y5 (l-152,804) receptor antagonists.
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DISCUSSION
In previous studies, we and others have shown that NPY
receptors modulate Ca2 influx (38, 56), K currents
(57, 58), and glutamate release (38, 59) from neuronal
cells. Moreover, NPY inhibits excitatory neurotransmis-
sion in the hippocampus (18), exogenous administra-
tion of NPY prominently suppresses limbic seizure
activity induced by KA (15), and NPY-deficient mice
develop more severe seizures in response to KA, sug-
gesting that NPY may act as an endogenous anticonvul-
sant agent. So, since NPY affects glutamatergic synaptic
transmission and neuronal excitability (5, 10, 12), it is
of great interest to investigate the functional role of the
NPY system in epileptic seizures. Indeed, little is known
about the signaling mechanism (mechanisms) that
underlie NPY receptor effects under epileptic condi-
tions.
In common with some other presynaptic metabo-
tropic receptors (60), the observed inhibitory effect
mediated by NPY Y1, Y2, and Y5 receptors did not work
through a cyclic AMP-dependent mechanism as it was
not influenced by PKA activator (8-Br-cAMP) or by its
inhibitor (H89). In fact, in our study we observed that
the activation or inhibition of PKA failed to modify
inhibition of glutamate release mediated by any of the
NPY receptors. In contrast, the role of PKC activation in
regulation of presynaptic function in general, and
glutamate release in particular, is well established in
synaptosomal studies (29, 60). In the present work, we
observed that the activation of PKC by a phorbol ester
(PMA) induced an increase of glutamate release. In
fact, it is well established that the activation of PKC by
phorbol esters leads to an increase in neurotransmitter
release from rat hippocampal slices (46), and mamma-
lian brains synaptosomes (29, 48), and also potentiates
excitatory postsynaptic currents (EPSCs) (61). NPY- or
Y2 receptor-mediated inhibition of glutamate release
under control conditions was abolished following PKC
activation. In contrast, when using synaptosomes ob-
tained from epileptic rats 6 h postinjection, we ob-
served no NPY receptor-mediated inhibition of gluta-
mate release (21). Moreover, phorbol esters did not
affect glutamate release, in contrast to what was ob-
served 24 h postinjection and in controls. These results
suggest that PKC can be highly active following status
epilepticus and somehow blocks the inhibition of glu-
Figure 6. Representative images of [35S]GTPS functional
binding in the rat hippocampal CA1, CA3, and DG at 6 h after
i.p. injection of saline (0.9% NaCl) or KA (10 mg/kg).
Visualization of all NPY receptor subtypes (Y1, Y2, Y5) with 3
M NPY-stimulated binding (A), nonspecific binding (B),
basal binding (C), and total block of NPY-stimulated binding
(3 M NPY30 M Y1, Y2, Y5 antagonists) (D) in saline-
treated rats. Y2 receptor functional binding (3 M NPY30
M Y1, Y5 antagonists) did not differ in CA1 and CA3
(arrows) between saline- (E) and KA-treated rats (F). No
functional Y2 receptor binding was detected in the DG. The
presence of PKC activator (300 nM PMA) did not affect Y2
receptor-mediated functional binding in either saline- (G) or
KA-injected rats (H).
Figure 7. Lack of effect of NPY, NPY(13–36), and PMA on
glutamate release evoked by 5 M ionomycin in control rat
hippocampal synaptosomes. Results represent the mean  se
of 4 to 8 independent experiments in different synaptosomal
preparations.
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tamate release induced by Y2 receptor activation. An-
other possible interpretation for our results is the
inhibition of PKC effects by NPY acting through Y1 and
Y5 receptors. As we show in the present study, in
epileptic rats (6 h post-kainate injection), NPY is not
efficient at inhibiting the release of glutamate; this
effect is similar to that observed after stimulation of Y2
receptors but different from the results obtained in the
presence of Y1 or Y5 agonists (21). The effect of NPY
under basal conditions and epileptic ones (24 h postin-
jection) is mediated mainly through Y2 receptors, but
after status epilepticus (6 h), when PKC is active, Y2
receptor activity is not linked to the efficient inhibition
of glutamate release. However, whether or not Y1 and
Y5 receptor activity can shortcut the effect of PKC in
stimulating the release of glutamate is an alternative
and attractive hypothesis. Future studies will determine
whether in epileptic rats (6 h) the blockade of Y2
receptors relieve the predominant effect of NPY at Y2
receptors, making Y1 and Y5 receptors sensitive to NPY
(as we previously reported in 45), and whether in this
condition NPY can efficiently block the stimulatory
effect of PKC.
It is clear that status epilepticus induces alterations in
the subcellular distribution of individual PKC isoforms
in a temporally and regionally specific manner (62). In
fact, we observed that by inhibiting PKC in synapto-
somes isolated 6 h postinjection with KA, Y2 receptors
recovered their inhibitory effect on glutamate release.
Moreover, analyzing the expression levels of phospho-
GluR1 (Ser-831), it is evident there is an increase of
PKC activity after status epilepticus. This increase was
significant in the CA1 subregion, in agreement with
other studies that show a differential activity of PKC
among brain regions or subregions (62). Also, Hussain
and Carpenter (63) showed that the presence and
function of PKC are age dependent and different
between Schaffer collateral-CA1 and Mossy fibers-CA3
pathways within the normal hippocampus. With the
present data, we cannot form definitive conclusions
about the mechanisms contributing to the differences
observed in the functional release of glutamate be-
tween 6 h and 24 h. We can, however, suggest that other
mechanisms able to shortcut/silent the stimulatory
effect of PKC on glutamate release (i.e., increased
activity of phosphatases) may be functional at 24 h but
not at 6 h postinjection. It is important to keep in mind
that phospho-GluR1 was used as a marker PKC activity,
but this approach cannot lead to conclusions about the
spatial and temporal activity of PKC at presynaptic sites,
especially important for the control of voltage-gated
calcium channels.
As already mentioned, several actions have been
attributed to PKC, including not only the enhancement
of Ca2 currents and elevation of cytosolic-free Ca2
resulting in increased neurotransmitter release (64),
inhibition of K channels (31), and activation of exo-
cytotic machinery downstream of Ca2 influx (30), but
also regulation of activity of NMDA receptors (65) or
1d-adrenergic receptors (66). However, the mecha-
nism (or mechanisms) whereby PKC blocks the inhib-
itory effect of Y2 receptors is unknown. Therefore, we
first tried to investigate whether PKC was acting directly
on the receptors or at the G-protein level. Our results
indicated that this might not be the case, in contrast to
what is known to happen with several other receptors
(65). Indeed, the [35S]GTPS binding assay we used to
assess the function of Y2 receptors gave similar results
under control and epileptic conditions with or without
the pharmacological activation of PKC with phorbol
ester, indicating that these receptors are not function-
ally directly regulated by PKC. So the precise mecha-
nism (or mechanisms) underlying the blockage of Y2
receptors are yet to be determined, but given that
modulation of ion channel activity is considered one of
the major target mechanisms, it is plausible that a good
target candidate for PKC could be the voltage-gated
Ca2 channels (VGCCs). In previous studies performed
by us and others, it was shown that NPY receptors
modulate (inhibit) the [Ca2]i response in the hip-
pocampus, and this was mainly due to the inhibition of
different VGCCs (45). If PKC is acting on VGCCs by
increasing Ca2 conductance, as we suggested in the
present study and as described by others (29), it is
plausible to suggest that this mechanism may account
for the cross-talk between PKC and Y1 (29) or PKC and
Y2 (present study) receptor function. A major unbal-
ance of the excitatory/inhibitory transmission occurs in
status epilepticus and causes a major shift toward
hyperexcitability, contributing to the generalization of
seizure activity and to tonic-clonic convulsions. Our
present demonstration that PKC contributes to the
increased release of glutamate and at the same time,
blocks a key inhibitory modulator (Y2 receptor) may
help to highlight the impact of the PKC/NPY cross-talk
in status epilepticus.
In summary, the present findings show a transient
loss of NPY- and Y2 receptor-mediated inhibition of
glutamate release following status epilepticus. We also
show that PKC is highly active and may contribute to
occlude the functional effects of Y2 receptors in inhib-
iting glutamate release. Since Y2 receptors are essential
for NPY regulation of limbic seizures originating in the
hippocampus, understanding the cell signaling that
underlies its effect under control and epileptic condi-
tions may be quite useful to find potential new treat-
ments for temporal lobe epilepsy.
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